Gerresheimer’s Creditors Extend Deadline as Barclays Cuts Rating and US Plant Closes

Barclays cuts Gerresheimer to Underweight as glass packaging lags, creditors extend loan deadline, and a US factory closure signals deep restructuring.

The Düsseldorf-based packaging specialist Gerresheimer is navigating a perfect storm of accounting irregularities, regulatory scrutiny, and operational restructuring. While creditors have granted the company breathing room, analysts are growing more cautious on the stock, and the closure of a US factory underscores the depth of the cost-cutting drive.

Barclays analyst Jonathon Unwin has downgraded Gerresheimer to “Underweight,” slashing the price target from €23 to €19. The bank’s reasoning is structural: Gerresheimer’s traditional strength in glass packaging for vials and ampoules is losing ground to the faster-growing market for injection systems. That sectoral shift, combined with the company’s delayed financial reporting, leaves the shares vulnerable. The stock has recovered from a February low of around €15.57 to trade at €23.80 — roughly 23% above its 50-day moving average — but remains down about 59% year-to-date.

Creditors Show Patience

The company’s most immediate financial pressure has eased, at least temporarily. Holders of Schuldschein loans totaling €870 million voted with 96% approval to extend the deadline for audited 2025 accounts to September 30, 2026. Management aims to publish the financial statements by June. That gives Gerresheimer a window to resolve the underlying accounting issues that have triggered a special investigation by Germany’s financial regulator, BaFin.

US Plant Closure and Impairments

In a move to streamline operations, Gerresheimer is shutting its glass plant in Chicago Heights, Illinois, eliminating 172 positions. Production of pharmaceutical specialty glass — including serum and infusion bottles — will be transferred to existing facilities in Italy and India. The closure is part of a broader transformation program aimed at improving capacity utilization and profitability.

The restructuring comes with a heavy price tag. The company expects impairment charges of between €220 million and €240 million in the 2025 accounts. These non-cash write-downs are primarily tied to the US glass business and technology projects at its Sensile Medical subsidiary.

Accounting Irregularities and Regulatory Heat

At the heart of the crisis are internal investigations into transactions during 2024 and 2025. The company is probing potential violations of internal policies and IFRS standards, specifically regarding the booking of bill-and-hold revenues and inventory valuation. For the 2024 financial year, Gerresheimer anticipates a revenue correction of approximately €35 million and an adjusted EBITDA adjustment of around €24 million. The audited 2025 accounts have yet to be filed.

The regulatory pressure is intensifying. BaFin is conducting a special audit of the company’s accounting practices, while the German auditor oversight body has opened proceedings against KPMG, which had issued an unqualified audit opinion on the flawed 2024 accounts. The annual general meeting has been postponed, and the first-quarter 2026 report has been delayed.

Outlook Hinges on Audit Completion

Despite the turmoil, management has issued a forecast for 2026, projecting revenue of €2.3 billion to €2.4 billion and an adjusted EBITDA margin of 18% to 19%. These targets are conditional on the completion of the pending audits and the resolution of the BaFin probe. The company also faces external headwinds from rising energy and raw material costs, which are squeezing margins in its energy-intensive glass and plastics operations.

For now, Gerresheimer has bought time with its creditors, but the path to restoring investor confidence remains steep. The June deadline for the audited accounts will be a critical test — and the outcome of the BaFin investigation could determine whether the company can move beyond its current crisis.